Background and objective
A retrospective review of consecutive patients between January 2012 and December 2018 receiving hypofractionated stereotactic radiotherapy (HSRT) to the cavity after resection for brain metastases was performed.
Treatment was delivered using an appropriately commissioned linear accelerator. The primary outcome was time to radiological or histological confirmation of local recurrence following completion of HSRT. Dose-fractionation regimens were converted to biologically 2 Gy-equivalent doses assuming α/β = 10 (EQD2). Multivariate Cox proportional hazards modelling was performed to determine hazard ratios (HR) with respective 95% confidence intervals (CI). The Log-rank test was used to determine p values taking statistical significance p < 0.05.
There were 134 patients and 144 cavities identified. The most common primary histologies were melanoma (n = 49) and lung (n = 32). 116 patients (87%) underwent a gross total resection. Median planning target volume (PTV) was 28 cm3 (range 2.4–149.2). Median EQD2 was 38.4 Gy (range 22.3–59.7) and 24 Gy in 3 fractions was the most common regimen. 12 (9%) patients demonstrated local recurrence at median interval 215 days (range 4–594). 7 (5%) patients experienced grade 3 or higher toxicities. In multivariate analysis, EQD2 was associated with local failure such that increased equivalent doses improved local control [HR = 0.79 and 95% CI 0.65–0.96, p = 0.0192]. There were no significant associations for primary histology, patient age, volume of residual disease, PTV volume or location.
This large series demonstrates that HSFRT to the surgical resection cavity for brain metastases has improved local control with increasing dose. Rates of grade 3 or higher toxicity were low overall.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Davis F, Dolecek T, McCarthy B, Villano J (2012) Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro-Oncology 14(9):1171–1177. https://doi.org/10.1093/neuonc/nos152
Schouten L, Rutten J, Huveneers H, Twijnstra A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10):2698–2705. https://doi.org/10.1002/cncr.10541
Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500. https://doi.org/10.1056/NEJM199002223220802
Noordijk E, Vecht C, Haaxma-Reiche H, Padberg G, Voormolen J, Hoekstra F et al (1994) The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29(4):711–717. https://doi.org/10.1016/0360-3016(94)90558-4
Patchell R, Tibbs P, Regine W, Dempsey R, Mohiuddin M, Kryscio R et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA 280(17):1485–1489. https://doi.org/10.1001/jama.280.17.1485
Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert B et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 Study. J Clin Oncol 29(2):134–141. https://doi.org/10.1200/JCO.2010.30.1655
Brown P, Ballman K, Cerhan J, Anderson SK, Carrero XW, Whitton AC et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1049–1060. https://doi.org/10.1016/S1470-2045(17)30441-2
Mahajan A, Ahmed S, McAleer M, Weinberg J, Li J, Brown P (2017) Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 18(8):1040–1048. https://doi.org/10.1016/S1470-2045(17)30414-X
Soffietti R, Kocher M, Abacioglu U, Villa S, Fauchon F, Baumert B (2013) A European Organisation for Research and Treatment of Cancer Phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31(1):65–72. https://doi.org/10.1200/JCO.2011.41.0639
Susko M, Yu Y, Ma L, Nakamura J, Fogh S, Raleigh D (2019) Preoperative dural contact and recurrence risk after surgical cavity stereotactic radiosurgery for brain metastases: new evidence in support of consensus guidelines. Adv Radiat Oncol 4(3):458–465. https://doi.org/10.1016/j.adro.2019.03.002
Kepka L, Tyc-Szczepaniak D, Osowiecka K, Sprawka A, Trąbska-Kluch B, Czeremszynska B (2017) Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial. Clin Transl Oncol 20(2):150–159
Minniti G, Scaringi C, Paolini S, Lanzetta G, Romano A, Cicone F (2016) Single-fraction versus multifraction (3 × 9 Gy) stereotactic radiosurgery for large (%3e2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys 95(4):1142–1148. https://doi.org/10.1016/j.ijrobp.2016.03.013
Pinkham M, Whitfield G, Brada M (2015) New developments in intracranial stereotactic radiotherapy for metastases. Clin Oncol 27(5):316–323. https://doi.org/10.1016/j.clon.2015.01.007
Soliman H, Myrehaug S, Tseng C, Ruschin M, Hashmi A, Mainprize T (2019) Image-guided, linac-based, surgical cavity-hypofractionated stereotactic radiotherapy in 5 daily fractions for brain metastases. Neurosurgery. https://doi.org/10.1093/neuros/nyz16
Choi C, Chang S, Gibbs I, Adler J, Harsh G, Lieberson R (2012) Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys 84(2):336–342. https://doi.org/10.1016/j.ijrobp.2011.12.009
Soliman H, Ruschin M, Angelov L, Brown P, Chiang V, Kirkpatrick JP (2017) Consensus contouring guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 100(2):436–442. https://doi.org/10.1016/j.ijrobp.2017.09.047
United States Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events Version 5.0. National Institutes of Health.
Kondziolka D, Shin S, Brunswick A, Kim I, Silverman J (2014) The biology of radiosurgery and its clinical applications for brain tumors. Neuro-Oncology 17(1):29–44. https://doi.org/10.1093/neuonc/nou284
Traylor J, Habib A, Patel R, Muir M, Gadot R, Briere T (2019) Fractionated stereotactic radiotherapy for local control of resected brain metastases. J Neuro-Oncol 144(2):343–350. https://doi.org/10.1007/s11060-019-03233-9
Combs S, Bilger A, Diehl C, Bretzinger E, Lorenz H, Oehlke O et al (2018) Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases. Cancer Med 7(6):2319–2327. https://doi.org/10.1002/cam4.1477
Keller A, Doré M, Cebula H, Thillays F, Proust F, Darié I et al (2017) Hypofractionated stereotactic radiation therapy to the resection bed for intracranial metastases. Int J Radiat Oncol Biol Phys 99(5):1179–1189. https://doi.org/10.1016/j.ijrobp.2017.08.014
Bilger A, Milanovic D, Lorenz H, Oehlke O, Urbach H, Schmucker M et al (2016) Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. Clin Neurol Neurosurg 142:81–86. https://doi.org/10.1016/j.clineuro.2016.01.008
Ayas A, Grau S, Jablonska K, Ruess D, Ruge M, Marnitz S (2018) Postoperative local fractionated radiotherapy for resected single brain metastases. Strahlenther Onkol 194(12):1163–1170. https://doi.org/10.1007/s00066-018-1368-1
Single fraction stereotactic radiosurgery compared with fractionated stereotactic radiosurgery in treating patients with resected metastatic brain disease (2019) ClinicalTrialsgov US National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04114981. Accessed 22 Dec 2019
Kumar A, Miller J, Hoffer S, Mansur D, Coffey M, Lo S (2018) Postoperative hypofractionated stereotactic brain radiation (HSRT) for resected brain metastases: improved local control with higher BED10. J Neuro-Oncol 139(2):449–454
Shin S, Vatner R, Tam M, Golfinos J, Narayana A, Kondziolka D et al (2015) Resection followed by involved-field fractionated radiotherapy in the management of single brain metastasis. Front Oncol. https://doi.org/10.3389/fonc.2015.00206
Chukwueke U, Batchelor T, Brastianos P (2016) Management of brain metastases in patients with melanoma. J Oncol Pract 12(6):536–542. https://doi.org/10.1200/JOP.2016.011882
Sperduto P, Chao S, Sneed P, Luo X, Suh J, Roberge D et al (2010) Diagnosis-Specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 77(3):655–661. https://doi.org/10.1016/j.ijrobp.2009.08.025
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Garimall, S., Shanker, M., Johns, E. et al. Evidence of dose-response following hypofractionated stereotactic radiotherapy to the cavity after surgery for brain metastases. J Neurooncol 146, 357–362 (2020). https://doi.org/10.1007/s11060-019-03383-w
- Brain metastases
- Hypofractionated stereotactic radiotherapy